| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 40 | 2023 | 762 | 7.160 |
Why?
|
| Cognition Disorders | 28 | 2016 | 555 | 3.470 |
Why?
|
| Brain Injuries, Traumatic | 13 | 2024 | 373 | 3.080 |
Why?
|
| Neuropsychological Tests | 32 | 2024 | 927 | 2.220 |
Why?
|
| Memory Disorders | 8 | 2024 | 236 | 2.160 |
Why?
|
| Neuropsychiatry | 6 | 2020 | 12 | 2.050 |
Why?
|
| Bipolar Disorder | 11 | 2023 | 347 | 1.920 |
Why?
|
| Cholinesterase Inhibitors | 5 | 2024 | 92 | 1.730 |
Why?
|
| Mental Disorders | 18 | 2014 | 818 | 1.540 |
Why?
|
| Neurosciences | 3 | 2017 | 50 | 1.490 |
Why?
|
| Indans | 2 | 2024 | 55 | 1.320 |
Why?
|
| Piperidines | 2 | 2024 | 201 | 1.210 |
Why?
|
| Crying | 6 | 2014 | 12 | 1.120 |
Why?
|
| Depressive Disorder, Major | 6 | 2023 | 400 | 1.120 |
Why?
|
| Mood Disorders | 6 | 2023 | 124 | 1.070 |
Why?
|
| Brain | 21 | 2023 | 2964 | 1.070 |
Why?
|
| Consciousness Disorders | 5 | 2023 | 23 | 1.050 |
Why?
|
| Affective Symptoms | 5 | 2014 | 60 | 1.010 |
Why?
|
| Psychotic Disorders | 5 | 2015 | 136 | 0.960 |
Why?
|
| Frontotemporal Dementia | 2 | 2023 | 40 | 0.960 |
Why?
|
| Nootropic Agents | 1 | 2024 | 27 | 0.950 |
Why?
|
| Laughter | 5 | 2014 | 10 | 0.930 |
Why?
|
| Aggression | 4 | 2014 | 224 | 0.910 |
Why?
|
| Alcoholism | 6 | 2022 | 230 | 0.870 |
Why?
|
| Consciousness | 1 | 2023 | 49 | 0.860 |
Why?
|
| Hypoxia-Ischemia, Brain | 3 | 2010 | 77 | 0.850 |
Why?
|
| Humans | 125 | 2024 | 123288 | 0.830 |
Why?
|
| Receptors, Cholinergic | 4 | 2011 | 84 | 0.810 |
Why?
|
| Lupus Erythematosus, Systemic | 8 | 2013 | 173 | 0.810 |
Why?
|
| Evoked Potentials, Auditory | 6 | 2004 | 51 | 0.800 |
Why?
|
| Nervous System Diseases | 7 | 2020 | 376 | 0.780 |
Why?
|
| Memory | 7 | 2024 | 363 | 0.760 |
Why?
|
| Forensic Psychiatry | 2 | 2013 | 13 | 0.730 |
Why?
|
| Psychomotor Performance | 5 | 2011 | 182 | 0.720 |
Why?
|
| Psychiatry | 4 | 2016 | 262 | 0.700 |
Why?
|
| Irritable Mood | 3 | 2022 | 8 | 0.700 |
Why?
|
| Functional Laterality | 8 | 2016 | 181 | 0.690 |
Why?
|
| Brain Concussion | 5 | 2023 | 226 | 0.680 |
Why?
|
| Cognition | 7 | 2018 | 736 | 0.680 |
Why?
|
| Adult | 50 | 2024 | 29093 | 0.670 |
Why?
|
| Acetylcholine | 4 | 2011 | 82 | 0.640 |
Why?
|
| Hippocampus | 9 | 2019 | 819 | 0.640 |
Why?
|
| Hallucinations | 2 | 2016 | 26 | 0.630 |
Why?
|
| Amnesia | 3 | 2023 | 20 | 0.630 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 377 | 0.610 |
Why?
|
| Attention | 9 | 2019 | 196 | 0.610 |
Why?
|
| Brain Injury, Chronic | 2 | 2013 | 21 | 0.610 |
Why?
|
| Confusion | 2 | 2020 | 16 | 0.600 |
Why?
|
| Antipsychotic Agents | 4 | 2015 | 373 | 0.590 |
Why?
|
| Diagnosis, Differential | 16 | 2017 | 1878 | 0.580 |
Why?
|
| Cholinergic Fibers | 3 | 2011 | 9 | 0.580 |
Why?
|
| Aphasia | 2 | 2015 | 14 | 0.570 |
Why?
|
| Neurology | 2 | 2010 | 108 | 0.540 |
Why?
|
| Male | 64 | 2024 | 60346 | 0.530 |
Why?
|
| Politics | 1 | 2017 | 58 | 0.530 |
Why?
|
| Severity of Illness Index | 12 | 2011 | 2861 | 0.520 |
Why?
|
| Capgras Syndrome | 1 | 2016 | 3 | 0.520 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2014 | 202 | 0.520 |
Why?
|
| Impulsive Behavior | 2 | 2014 | 144 | 0.520 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2024 | 238 | 0.510 |
Why?
|
| Expert Testimony | 2 | 2013 | 36 | 0.500 |
Why?
|
| Middle Aged | 39 | 2024 | 26095 | 0.500 |
Why?
|
| Dopamine Agents | 2 | 2006 | 28 | 0.500 |
Why?
|
| Recovery of Function | 5 | 2019 | 437 | 0.490 |
Why?
|
| Pseudobulbar Palsy | 2 | 2005 | 4 | 0.490 |
Why?
|
| Dementia | 3 | 2013 | 448 | 0.490 |
Why?
|
| Stroke Rehabilitation | 2 | 2005 | 59 | 0.480 |
Why?
|
| Journalism, Medical | 1 | 2015 | 9 | 0.480 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2015 | 44 | 0.470 |
Why?
|
| Connectome | 3 | 2023 | 80 | 0.460 |
Why?
|
| Double-Blind Method | 6 | 2024 | 1602 | 0.460 |
Why?
|
| West Nile Fever | 2 | 2008 | 139 | 0.460 |
Why?
|
| Football | 1 | 2013 | 30 | 0.430 |
Why?
|
| Schizophrenia | 4 | 2015 | 299 | 0.420 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 195 | 0.410 |
Why?
|
| Mental Status Schedule | 2 | 2010 | 44 | 0.410 |
Why?
|
| Behavioral Symptoms | 1 | 2013 | 25 | 0.410 |
Why?
|
| Psychotropic Drugs | 1 | 2014 | 124 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2023 | 3553 | 0.410 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 3681 | 0.410 |
Why?
|
| Neurotransmitter Agents | 3 | 2008 | 145 | 0.400 |
Why?
|
| Violence | 1 | 2013 | 115 | 0.390 |
Why?
|
| Post-Concussion Syndrome | 3 | 2013 | 54 | 0.390 |
Why?
|
| Phenylcarbamates | 2 | 2009 | 15 | 0.390 |
Why?
|
| Psychiatric Status Rating Scales | 10 | 2015 | 803 | 0.380 |
Why?
|
| Female | 48 | 2024 | 65630 | 0.370 |
Why?
|
| Veterans | 4 | 2023 | 1738 | 0.370 |
Why?
|
| Electroencephalography | 4 | 2015 | 857 | 0.360 |
Why?
|
| Indians, North American | 2 | 2010 | 59 | 0.360 |
Why?
|
| Treatment Outcome | 14 | 2024 | 12176 | 0.350 |
Why?
|
| Military Personnel | 2 | 2023 | 209 | 0.350 |
Why?
|
| Delirium | 2 | 2024 | 47 | 0.350 |
Why?
|
| Suicide | 1 | 2013 | 175 | 0.350 |
Why?
|
| Capital Punishment | 1 | 2010 | 3 | 0.340 |
Why?
|
| Neuroprotective Agents | 2 | 2009 | 150 | 0.340 |
Why?
|
| Cerebral Cortex | 5 | 2019 | 448 | 0.340 |
Why?
|
| Public Policy | 1 | 2010 | 51 | 0.330 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 226 | 0.320 |
Why?
|
| Injury Severity Score | 5 | 2019 | 221 | 0.320 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2015 | 105 | 0.320 |
Why?
|
| Reflex | 1 | 2009 | 52 | 0.310 |
Why?
|
| Geriatric Assessment | 1 | 2010 | 169 | 0.310 |
Why?
|
| Amygdala | 3 | 2018 | 81 | 0.310 |
Why?
|
| Affect | 4 | 2008 | 158 | 0.310 |
Why?
|
| Central Nervous System Stimulants | 4 | 2016 | 125 | 0.310 |
Why?
|
| Physical Therapy Modalities | 2 | 2005 | 49 | 0.300 |
Why?
|
| Insanity Defense | 1 | 2008 | 3 | 0.300 |
Why?
|
| Neuroanatomy | 2 | 2023 | 11 | 0.300 |
Why?
|
| Crime | 1 | 2008 | 25 | 0.290 |
Why?
|
| White Matter | 2 | 2024 | 180 | 0.290 |
Why?
|
| Stroke | 5 | 2015 | 958 | 0.290 |
Why?
|
| Depression | 4 | 2009 | 1229 | 0.290 |
Why?
|
| Dibenzothiazepines | 1 | 2007 | 14 | 0.290 |
Why?
|
| Aged | 16 | 2024 | 19180 | 0.290 |
Why?
|
| Rivastigmine | 3 | 2021 | 17 | 0.280 |
Why?
|
| Physician-Patient Relations | 1 | 2010 | 427 | 0.270 |
Why?
|
| Alzheimer Disease | 3 | 2011 | 764 | 0.260 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1084 | 0.260 |
Why?
|
| Hiccup | 1 | 2006 | 6 | 0.260 |
Why?
|
| Methylphenidate | 3 | 2016 | 55 | 0.260 |
Why?
|
| Adrenergic Agents | 1 | 2006 | 12 | 0.260 |
Why?
|
| Behavioral Sciences | 1 | 2006 | 8 | 0.260 |
Why?
|
| Neuropsychology | 1 | 2006 | 23 | 0.250 |
Why?
|
| Hemiplegia | 1 | 2005 | 40 | 0.250 |
Why?
|
| Paresis | 1 | 2005 | 36 | 0.240 |
Why?
|
| Motor Skills | 1 | 2005 | 83 | 0.240 |
Why?
|
| Specialization | 1 | 2006 | 76 | 0.240 |
Why?
|
| Amantadine | 1 | 2004 | 10 | 0.240 |
Why?
|
| Upper Extremity | 1 | 2005 | 53 | 0.240 |
Why?
|
| Disability Evaluation | 3 | 2019 | 191 | 0.240 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2021 | 623 | 0.240 |
Why?
|
| Research Design | 1 | 2009 | 679 | 0.240 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2004 | 9 | 0.240 |
Why?
|
| Neurologic Examination | 5 | 2008 | 195 | 0.230 |
Why?
|
| Psychosurgery | 1 | 2004 | 27 | 0.230 |
Why?
|
| Healthy Aging | 1 | 2024 | 8 | 0.230 |
Why?
|
| Mental Competency | 1 | 2024 | 51 | 0.220 |
Why?
|
| Emotions | 3 | 2019 | 362 | 0.220 |
Why?
|
| Comorbidity | 3 | 2014 | 1497 | 0.220 |
Why?
|
| Exercise Therapy | 1 | 2005 | 152 | 0.220 |
Why?
|
| Neuroimaging | 5 | 2019 | 332 | 0.220 |
Why?
|
| Hospital Mortality | 1 | 2008 | 1013 | 0.220 |
Why?
|
| Myelin Sheath | 1 | 2024 | 132 | 0.210 |
Why?
|
| Analysis of Variance | 5 | 2007 | 1012 | 0.210 |
Why?
|
| Critical Care | 1 | 2008 | 648 | 0.210 |
Why?
|
| Substance-Related Disorders | 2 | 2020 | 458 | 0.200 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 2115 | 0.200 |
Why?
|
| Magnetoencephalography | 5 | 2011 | 33 | 0.200 |
Why?
|
| Valproic Acid | 2 | 2022 | 165 | 0.200 |
Why?
|
| Delusions | 2 | 2015 | 17 | 0.200 |
Why?
|
| Young Adult | 7 | 2024 | 8871 | 0.200 |
Why?
|
| Regression Analysis | 5 | 2013 | 773 | 0.190 |
Why?
|
| Prisoners | 1 | 2021 | 33 | 0.190 |
Why?
|
| Thalamus | 2 | 2018 | 85 | 0.190 |
Why?
|
| Dominance, Cerebral | 1 | 2000 | 54 | 0.180 |
Why?
|
| Central Nervous System Agents | 1 | 2000 | 15 | 0.180 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 17 | 0.180 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 214 | 0.170 |
Why?
|
| Hospitalization | 1 | 2008 | 1737 | 0.170 |
Why?
|
| Rehabilitation Centers | 1 | 2020 | 36 | 0.170 |
Why?
|
| Conversion Disorder | 1 | 2020 | 9 | 0.170 |
Why?
|
| Physical and Rehabilitation Medicine | 1 | 2020 | 33 | 0.170 |
Why?
|
| Electroconvulsive Therapy | 2 | 2014 | 66 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2017 | 6033 | 0.160 |
Why?
|
| Acceptance and Commitment Therapy | 1 | 2020 | 40 | 0.160 |
Why?
|
| Chronic Traumatic Encephalopathy | 1 | 2019 | 6 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 5 | 2013 | 289 | 0.160 |
Why?
|
| Glasgow Coma Scale | 2 | 2011 | 203 | 0.160 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2019 | 15 | 0.160 |
Why?
|
| Facial Expression | 1 | 2019 | 28 | 0.160 |
Why?
|
| Sensory Thresholds | 1 | 1999 | 33 | 0.160 |
Why?
|
| Biomechanical Phenomena | 2 | 2011 | 245 | 0.160 |
Why?
|
| Lithium Compounds | 1 | 2018 | 14 | 0.150 |
Why?
|
| Habenula | 1 | 2018 | 45 | 0.150 |
Why?
|
| Spatial Memory | 1 | 2017 | 37 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2000 | 298 | 0.140 |
Why?
|
| Glutamic Acid | 2 | 2011 | 200 | 0.140 |
Why?
|
| Sertraline | 2 | 2009 | 44 | 0.140 |
Why?
|
| Choline | 4 | 2013 | 54 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2011 | 6390 | 0.140 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 131 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2845 | 0.140 |
Why?
|
| Factor Analysis, Statistical | 1 | 2017 | 229 | 0.140 |
Why?
|
| Encephalitis | 1 | 2017 | 109 | 0.130 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2016 | 20 | 0.130 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 624 | 0.130 |
Why?
|
| Aspartic Acid | 3 | 2011 | 75 | 0.130 |
Why?
|
| Frontal Lobe | 3 | 2013 | 110 | 0.120 |
Why?
|
| Prognosis | 4 | 2019 | 4518 | 0.120 |
Why?
|
| Range of Motion, Articular | 2 | 2005 | 73 | 0.120 |
Why?
|
| Behavior, Animal | 1 | 2017 | 477 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2011 | 3236 | 0.120 |
Why?
|
| Anxiety Disorders | 2 | 2014 | 677 | 0.110 |
Why?
|
| Executive Function | 2 | 2016 | 106 | 0.110 |
Why?
|
| Creatine | 2 | 2011 | 41 | 0.110 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2015 | 140 | 0.110 |
Why?
|
| Length of Stay | 2 | 2011 | 1291 | 0.110 |
Why?
|
| Volition | 2 | 2006 | 11 | 0.110 |
Why?
|
| Referral and Consultation | 3 | 2024 | 528 | 0.110 |
Why?
|
| Terminology as Topic | 2 | 2008 | 228 | 0.110 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 54 | 0.100 |
Why?
|
| Multiple Sclerosis | 2 | 2007 | 335 | 0.100 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2012 | 20 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2019 | 16081 | 0.100 |
Why?
|
| United States | 6 | 2023 | 10657 | 0.100 |
Why?
|
| Blast Injuries | 1 | 2012 | 58 | 0.100 |
Why?
|
| Inpatients | 2 | 2018 | 494 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2023 | 4692 | 0.100 |
Why?
|
| Forensic Medicine | 1 | 2011 | 12 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 957 | 0.090 |
Why?
|
| Neurobiology | 1 | 2011 | 25 | 0.090 |
Why?
|
| Rest | 1 | 2011 | 58 | 0.090 |
Why?
|
| Trauma Severity Indices | 1 | 2011 | 87 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2011 | 3341 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2023 | 202 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 442 | 0.090 |
Why?
|
| Schizophrenic Psychology | 2 | 2002 | 81 | 0.090 |
Why?
|
| Economics | 1 | 2010 | 12 | 0.090 |
Why?
|
| Language Disorders | 1 | 2010 | 24 | 0.090 |
Why?
|
| Supreme Court Decisions | 1 | 2010 | 14 | 0.090 |
Why?
|
| Antidepressive Agents | 2 | 2018 | 288 | 0.080 |
Why?
|
| Adolescent | 6 | 2019 | 19129 | 0.080 |
Why?
|
| Animals | 7 | 2017 | 33853 | 0.080 |
Why?
|
| Evoked Potentials, Somatosensory | 2 | 1999 | 47 | 0.080 |
Why?
|
| Phenotype | 1 | 1999 | 4225 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2058 | 0.080 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2009 | 26 | 0.080 |
Why?
|
| Citalopram | 1 | 2009 | 30 | 0.080 |
Why?
|
| Capsules | 1 | 2009 | 21 | 0.080 |
Why?
|
| International Classification of Diseases | 1 | 2010 | 90 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2010 | 148 | 0.080 |
Why?
|
| Research | 1 | 2011 | 262 | 0.080 |
Why?
|
| Atrophy | 2 | 2007 | 226 | 0.080 |
Why?
|
| Interpersonal Relations | 1 | 2010 | 227 | 0.080 |
Why?
|
| Time | 1 | 2009 | 94 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2011 | 427 | 0.080 |
Why?
|
| Antibodies | 1 | 2010 | 371 | 0.080 |
Why?
|
| Motor Activity | 2 | 2017 | 523 | 0.080 |
Why?
|
| Consensus | 2 | 2023 | 612 | 0.080 |
Why?
|
| Neurochemistry | 1 | 2008 | 5 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2010 | 145 | 0.070 |
Why?
|
| Medical Records | 1 | 2009 | 190 | 0.070 |
Why?
|
| Dissociative Disorders | 1 | 2008 | 10 | 0.070 |
Why?
|
| Quetiapine Fumarate | 1 | 2007 | 16 | 0.070 |
Why?
|
| Prevalence | 2 | 2021 | 2409 | 0.070 |
Why?
|
| Presenilin-2 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Sex Factors | 2 | 2003 | 1261 | 0.070 |
Why?
|
| Presenilin-1 | 1 | 2007 | 52 | 0.070 |
Why?
|
| Wasting Disease, Chronic | 1 | 2007 | 1 | 0.070 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2007 | 21 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 726 | 0.070 |
Why?
|
| Disease Progression | 2 | 2011 | 2031 | 0.070 |
Why?
|
| Accidents, Traffic | 1 | 2007 | 105 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1316 | 0.070 |
Why?
|
| Neurosecretory Systems | 1 | 2007 | 23 | 0.070 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2006 | 8 | 0.070 |
Why?
|
| Intelligence Tests | 1 | 2007 | 57 | 0.070 |
Why?
|
| Disease Management | 1 | 2010 | 516 | 0.070 |
Why?
|
| Expressed Emotion | 1 | 2006 | 9 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2019 | 0.070 |
Why?
|
| Lithium Carbonate | 1 | 2006 | 21 | 0.070 |
Why?
|
| Biogenic Amines | 1 | 2006 | 19 | 0.070 |
Why?
|
| Incidence | 2 | 2011 | 3055 | 0.060 |
Why?
|
| Age Factors | 2 | 2019 | 2808 | 0.060 |
Why?
|
| Illusions | 1 | 2006 | 8 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2006 | 220 | 0.060 |
Why?
|
| Cytokines | 1 | 2011 | 1266 | 0.060 |
Why?
|
| Demography | 1 | 2007 | 239 | 0.060 |
Why?
|
| Health Surveys | 1 | 2007 | 243 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2006 | 106 | 0.060 |
Why?
|
| Gyrus Cinguli | 2 | 2023 | 113 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2006 | 101 | 0.060 |
Why?
|
| Education | 1 | 2006 | 105 | 0.060 |
Why?
|
| Patient Selection | 1 | 2009 | 683 | 0.060 |
Why?
|
| Diazepam | 1 | 2004 | 21 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2005 | 279 | 0.060 |
Why?
|
| Restraint, Physical | 1 | 2005 | 27 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 321 | 0.060 |
Why?
|
| Arm | 1 | 2005 | 75 | 0.060 |
Why?
|
| Psychological Tests | 1 | 2005 | 91 | 0.060 |
Why?
|
| History, Ancient | 1 | 2004 | 54 | 0.060 |
Why?
|
| Cooperative Behavior | 2 | 2006 | 219 | 0.060 |
Why?
|
| Narcotics | 1 | 2004 | 63 | 0.060 |
Why?
|
| Cognitive Aging | 1 | 2024 | 2 | 0.060 |
Why?
|
| Demyelinating Diseases | 1 | 2004 | 67 | 0.060 |
Why?
|
| Inflammation | 1 | 2011 | 1404 | 0.060 |
Why?
|
| Colorado | 3 | 2011 | 22 | 0.060 |
Why?
|
| Nerve Net | 1 | 2007 | 238 | 0.060 |
Why?
|
| Age of Onset | 1 | 2006 | 581 | 0.060 |
Why?
|
| Physostigmine | 1 | 2004 | 9 | 0.060 |
Why?
|
| History, 19th Century | 1 | 2004 | 116 | 0.060 |
Why?
|
| Time Factors | 2 | 2007 | 6223 | 0.060 |
Why?
|
| Methadone | 1 | 2004 | 124 | 0.060 |
Why?
|
| North America | 1 | 2004 | 239 | 0.060 |
Why?
|
| Corpus Callosum | 1 | 2024 | 98 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2005 | 371 | 0.060 |
Why?
|
| Hypnotics and Sedatives | 1 | 2004 | 135 | 0.050 |
Why?
|
| Akinetic Mutism | 1 | 2003 | 1 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2005 | 1172 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2023 | 86 | 0.050 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2003 | 5 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2003 | 269 | 0.050 |
Why?
|
| Physician's Role | 1 | 2004 | 165 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2004 | 381 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2006 | 269 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2005 | 378 | 0.050 |
Why?
|
| Auditory Cortex | 1 | 2002 | 29 | 0.050 |
Why?
|
| Geriatric Psychiatry | 1 | 2002 | 10 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2005 | 376 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2005 | 456 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2002 | 38 | 0.050 |
Why?
|
| Prefrontal Cortex | 1 | 2023 | 177 | 0.050 |
Why?
|
| Unconsciousness | 1 | 2001 | 17 | 0.050 |
Why?
|
| Acute Disease | 1 | 2004 | 1093 | 0.050 |
Why?
|
| Transdermal Patch | 1 | 2021 | 8 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2003 | 224 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 327 | 0.050 |
Why?
|
| Myelinolysis, Central Pontine | 1 | 2000 | 4 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 4300 | 0.040 |
Why?
|
| Psychomotor Disorders | 1 | 2000 | 28 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2020 | 677 | 0.040 |
Why?
|
| Curriculum | 1 | 2006 | 716 | 0.040 |
Why?
|
| Rehabilitation Research | 1 | 2020 | 1 | 0.040 |
Why?
|
| Corpus Striatum | 1 | 2000 | 89 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 490 | 0.040 |
Why?
|
| Epilepsies, Partial | 1 | 2000 | 91 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2024 | 493 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2021 | 335 | 0.040 |
Why?
|
| Magnetics | 1 | 1999 | 41 | 0.040 |
Why?
|
| Social Stigma | 1 | 2020 | 72 | 0.040 |
Why?
|
| Happiness | 1 | 2019 | 10 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 1999 | 86 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2020 | 93 | 0.040 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2000 | 119 | 0.040 |
Why?
|
| Mass Screening | 1 | 2005 | 779 | 0.040 |
Why?
|
| Reaction Time | 1 | 2000 | 170 | 0.040 |
Why?
|
| Glasgow Outcome Scale | 1 | 2019 | 46 | 0.040 |
Why?
|
| Decision Making | 1 | 2024 | 652 | 0.040 |
Why?
|
| Evoked Potentials | 1 | 2019 | 139 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1238 | 0.040 |
Why?
|
| Reference Values | 1 | 2000 | 701 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2019 | 115 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5061 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 419 | 0.040 |
Why?
|
| Gray Matter | 1 | 2018 | 30 | 0.040 |
Why?
|
| Gliosis | 1 | 2017 | 32 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2019 | 279 | 0.040 |
Why?
|
| Syndrome | 1 | 2000 | 1115 | 0.040 |
Why?
|
| Fear | 1 | 2019 | 201 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 1999 | 220 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 751 | 0.040 |
Why?
|
| Maze Learning | 1 | 2017 | 128 | 0.040 |
Why?
|
| Aging | 1 | 2024 | 1185 | 0.030 |
Why?
|
| Brain Chemistry | 2 | 2009 | 122 | 0.030 |
Why?
|
| Microglia | 1 | 2017 | 92 | 0.030 |
Why?
|
| Biomarkers | 2 | 2011 | 2955 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 299 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 466 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2015 | 107 | 0.030 |
Why?
|
| Astrocytes | 1 | 2017 | 250 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 669 | 0.030 |
Why?
|
| Software | 1 | 1999 | 674 | 0.030 |
Why?
|
| Caregivers | 1 | 2020 | 573 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 1414 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1419 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 291 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2010 | 1389 | 0.030 |
Why?
|
| Child | 2 | 2019 | 24269 | 0.030 |
Why?
|
| Risk Factors | 2 | 2004 | 10033 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2013 | 139 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2004 | 3019 | 0.020 |
Why?
|
| Creatinine | 1 | 2013 | 382 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 124 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 586 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 3385 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2011 | 396 | 0.020 |
Why?
|
| Neurofibrillary Tangles | 1 | 2007 | 26 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2007 | 40 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2010 | 243 | 0.020 |
Why?
|
| Pituitary Hormones, Anterior | 1 | 2007 | 3 | 0.020 |
Why?
|
| Disease Reservoirs | 1 | 2007 | 35 | 0.020 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2007 | 21 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 139 | 0.020 |
Why?
|
| Thyrotropin | 1 | 2007 | 60 | 0.020 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2007 | 14 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2007 | 77 | 0.020 |
Why?
|
| Prolactin | 1 | 2007 | 107 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 2007 | 56 | 0.020 |
Why?
|
| Introns | 1 | 2007 | 300 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 355 | 0.020 |
Why?
|
| Antiemetics | 1 | 2006 | 23 | 0.020 |
Why?
|
| Stereotyping | 1 | 2006 | 18 | 0.020 |
Why?
|
| Benzamides | 1 | 2006 | 105 | 0.020 |
Why?
|
| Point Mutation | 1 | 2007 | 348 | 0.020 |
Why?
|
| Saliva | 1 | 2006 | 113 | 0.020 |
Why?
|
| Axons | 1 | 2009 | 380 | 0.020 |
Why?
|
| Vomiting | 1 | 2006 | 115 | 0.020 |
Why?
|
| Mental Processes | 1 | 2005 | 40 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2005 | 52 | 0.020 |
Why?
|
| Skull | 1 | 2006 | 141 | 0.020 |
Why?
|
| Carbamazepine | 1 | 2005 | 48 | 0.020 |
Why?
|
| MEDLINE | 1 | 2005 | 20 | 0.020 |
Why?
|
| Central Nervous System Diseases | 1 | 2005 | 105 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 807 | 0.010 |
Why?
|
| Language | 1 | 2005 | 202 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 470 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2005 | 253 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 822 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1690 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2005 | 258 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2004 | 354 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 17557 | 0.010 |
Why?
|
| Median Nerve | 1 | 1999 | 15 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1999 | 316 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1999 | 316 | 0.010 |
Why?
|